Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06058377
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2023-09-27
Brief Title:
Adding an Immunotherapy Drug MEDI4736 Durvalumab to the Usual Chemotherapy Treatment Paclitaxel Cyclophosphamide and Doxorubicin for Stage II-III Breast Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
NCI-2023-04566
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Cancer Institute NCI
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None